Microrna-141 Is Associated With Hepatic Steatosis by Downregulating the Sirtuin1/Amp-Activated Protein Kinase Pathway in Hepatocytes Publisher Pubmed



Yousefi Z¹ ; Nourbakhsh M^{1, 2} ; Abdolvahabi Z³ ; Ghorbanhosseini SS¹ ; Hesari Z^{4, 5} ; Yarahmadi S¹ ; Ezzatimobasser S¹ ; Seiri P⁶ ; Borji M⁷ ; Meshkani R⁸ ; Malek M⁹
Source: Journal of Cellular Physiology Published:2020

Abstract

Sirtuin1 (SIRT1) is a crucial regulator of metabolism and it is implicated in the metabolic pathophysiology of several disorders inclusive of Type 2 diabetes and fatty liver disease (NAFLD). The aim of this study was to investigate the role of miR-141 in hepatic steatosis via regulation of SIRT1/AMP-activated protein kinase (AMPK) pathway in hepatocytes. Liver hepatocellular cells (HepG2) were treated with high concentration of glucose to be subsequently used for the assessment of miR-141 and SIRT1 levels in a model of hepatic steatosis. On the other hand, cells were transfected with miR-141 to investigate its effect on hepatocyte steatosis and viability as well as SIRT1 expression and activity along with AMPK phosphorylation. Targeting of SIRT1 by miR-141 was evaluated by bioinformatics tools and confirmed by luciferase reporter assay. Following the intracellular accumulation of lipids in HepG2 cells, the level of miR-141 was increased while SIRT1 mRNA and protein levels, as well as AMPK phosphorylation, was decreased. Transfection with miR-141 mimic significantly downregulated SIRT1 expression and activity while miR-141 inhibitor had the opposite effects. Additionally, modulation of miR-141 levels significantly influenced AMPK phosphorylation status. The results of luciferase reporter assay verified SIRT1 to be directly targeted by miR-141. miR-141 could effectively suppress SIRT1 and lead to decreased AMPK phosphorylation in HepG2 cells. Thus, miR-141/SIRT1/AMPK signaling pathway may be considered a potential target for the therapeutic management of NAFLD. © 2019 Wiley Periodicals, Inc.